nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—PTK2B—Alzheimer's disease	0.301	0.56	CbGaD
Crizotinib—IGF1R—Alzheimer's disease	0.236	0.44	CbGaD
Crizotinib—Renal cyst—Memantine—Alzheimer's disease	0.00629	0.0457	CcSEcCtD
Crizotinib—Renal cyst—Rivastigmine—Alzheimer's disease	0.00616	0.0447	CcSEcCtD
Crizotinib—Electrocardiogram QT corrected interval prolonged—Memantine—Alzheimer's disease	0.00316	0.023	CcSEcCtD
Crizotinib—Disorder sight—Galantamine—Alzheimer's disease	0.00254	0.0185	CcSEcCtD
Crizotinib—Sinus bradycardia—Galantamine—Alzheimer's disease	0.00247	0.0179	CcSEcCtD
Crizotinib—Periorbital oedema—Donepezil—Alzheimer's disease	0.00237	0.0172	CcSEcCtD
Crizotinib—Periorbital oedema—Rivastigmine—Alzheimer's disease	0.00211	0.0153	CcSEcCtD
Crizotinib—Electrocardiogram QT prolonged—Galantamine—Alzheimer's disease	0.00189	0.0137	CcSEcCtD
Crizotinib—Disorder sight—Memantine—Alzheimer's disease	0.00179	0.013	CcSEcCtD
Crizotinib—Disorder sight—Rivastigmine—Alzheimer's disease	0.00175	0.0127	CcSEcCtD
Crizotinib—Balance disorder—Memantine—Alzheimer's disease	0.00156	0.0113	CcSEcCtD
Crizotinib—Transaminases increased—Donepezil—Alzheimer's disease	0.00154	0.0112	CcSEcCtD
Crizotinib—Balance disorder—Rivastigmine—Alzheimer's disease	0.00152	0.0111	CcSEcCtD
Crizotinib—Visual acuity reduced—Memantine—Alzheimer's disease	0.00143	0.0104	CcSEcCtD
Crizotinib—Generalised oedema—Rivastigmine—Alzheimer's disease	0.0014	0.0102	CcSEcCtD
Crizotinib—Neuralgia—Donepezil—Alzheimer's disease	0.00135	0.00981	CcSEcCtD
Crizotinib—Electrocardiogram QT prolonged—Memantine—Alzheimer's disease	0.00133	0.00964	CcSEcCtD
Crizotinib—Electrocardiogram QT prolonged—Rivastigmine—Alzheimer's disease	0.0013	0.00943	CcSEcCtD
Crizotinib—Neuralgia—Memantine—Alzheimer's disease	0.00123	0.00891	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Galantamine—Alzheimer's disease	0.00121	0.0088	CcSEcCtD
Crizotinib—Neuralgia—Rivastigmine—Alzheimer's disease	0.0012	0.00872	CcSEcCtD
Crizotinib—Abscess—Donepezil—Alzheimer's disease	0.00119	0.00862	CcSEcCtD
Crizotinib—Abscess—Memantine—Alzheimer's disease	0.00108	0.00782	CcSEcCtD
Crizotinib—Abscess—Rivastigmine—Alzheimer's disease	0.00105	0.00765	CcSEcCtD
Crizotinib—Gamma-glutamyltransferase increased—Memantine—Alzheimer's disease	0.00104	0.00752	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Galantamine—Alzheimer's disease	0.00101	0.00734	CcSEcCtD
Crizotinib—Gait disturbance—Donepezil—Alzheimer's disease	0.000961	0.00699	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Donepezil—Alzheimer's disease	0.000938	0.00682	CcSEcCtD
Crizotinib—Gait disturbance—Memantine—Alzheimer's disease	0.000873	0.00634	CcSEcCtD
Crizotinib—Respiratory failure—Memantine—Alzheimer's disease	0.000868	0.0063	CcSEcCtD
Crizotinib—Gait disturbance—Rivastigmine—Alzheimer's disease	0.000854	0.00621	CcSEcCtD
Crizotinib—Pulmonary embolism—Memantine—Alzheimer's disease	0.000852	0.00619	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Memantine—Alzheimer's disease	0.000852	0.00619	CcSEcCtD
Crizotinib—Respiratory failure—Rivastigmine—Alzheimer's disease	0.000849	0.00617	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Rivastigmine—Alzheimer's disease	0.000833	0.00606	CcSEcCtD
Crizotinib—Pulmonary embolism—Rivastigmine—Alzheimer's disease	0.000833	0.00606	CcSEcCtD
Crizotinib—Sepsis—Donepezil—Alzheimer's disease	0.000814	0.00592	CcSEcCtD
Crizotinib—Neuropathy—Memantine—Alzheimer's disease	0.0008	0.00581	CcSEcCtD
Crizotinib—Hypokalaemia—Galantamine—Alzheimer's disease	0.0008	0.00581	CcSEcCtD
Crizotinib—Fluid retention—Rivastigmine—Alzheimer's disease	0.000791	0.00575	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Donepezil—Alzheimer's disease	0.000783	0.00569	CcSEcCtD
Crizotinib—Neuropathy—Rivastigmine—Alzheimer's disease	0.000782	0.00569	CcSEcCtD
Crizotinib—Muscular weakness—Galantamine—Alzheimer's disease	0.000775	0.00563	CcSEcCtD
Crizotinib—Sepsis—Memantine—Alzheimer's disease	0.000739	0.00537	CcSEcCtD
Crizotinib—Sepsis—Rivastigmine—Alzheimer's disease	0.000723	0.00526	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Memantine—Alzheimer's disease	0.000711	0.00517	CcSEcCtD
Crizotinib—Hepatic function abnormal—Memantine—Alzheimer's disease	0.000708	0.00514	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Galantamine—Alzheimer's disease	0.000706	0.00513	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Rivastigmine—Alzheimer's disease	0.000696	0.00505	CcSEcCtD
Crizotinib—Hepatic failure—Memantine—Alzheimer's disease	0.000688	0.005	CcSEcCtD
Crizotinib—Weight decreased—Galantamine—Alzheimer's disease	0.000687	0.00499	CcSEcCtD
Crizotinib—Pneumonia—Galantamine—Alzheimer's disease	0.000681	0.00495	CcSEcCtD
Crizotinib—Neuropathy peripheral—Galantamine—Alzheimer's disease	0.000664	0.00482	CcSEcCtD
Crizotinib—Face oedema—Donepezil—Alzheimer's disease	0.000658	0.00478	CcSEcCtD
Crizotinib—Hepatobiliary disease—Galantamine—Alzheimer's disease	0.000641	0.00465	CcSEcCtD
Crizotinib—Hypokalaemia—Donepezil—Alzheimer's disease	0.00062	0.0045	CcSEcCtD
Crizotinib—Bradycardia—Galantamine—Alzheimer's disease	0.000619	0.0045	CcSEcCtD
Crizotinib—Diplopia—Memantine—Alzheimer's disease	0.000618	0.00449	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Donepezil—Alzheimer's disease	0.000613	0.00446	CcSEcCtD
Crizotinib—Diplopia—Rivastigmine—Alzheimer's disease	0.000605	0.0044	CcSEcCtD
Crizotinib—Muscular weakness—Donepezil—Alzheimer's disease	0.000601	0.00437	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Donepezil—Alzheimer's disease	0.000601	0.00437	CcSEcCtD
Crizotinib—Urinary tract disorder—Galantamine—Alzheimer's disease	0.0006	0.00436	CcSEcCtD
Crizotinib—Oedema peripheral—Galantamine—Alzheimer's disease	0.000599	0.00435	CcSEcCtD
Crizotinib—Urethral disorder—Galantamine—Alzheimer's disease	0.000596	0.00433	CcSEcCtD
Crizotinib—Visual impairment—Galantamine—Alzheimer's disease	0.000586	0.00426	CcSEcCtD
Crizotinib—Face oedema—Rivastigmine—Alzheimer's disease	0.000584	0.00424	CcSEcCtD
Crizotinib—Eye disorder—Galantamine—Alzheimer's disease	0.000568	0.00413	CcSEcCtD
Crizotinib—Cardiac disorder—Galantamine—Alzheimer's disease	0.000564	0.0041	CcSEcCtD
Crizotinib—Hypokalaemia—Memantine—Alzheimer's disease	0.000563	0.00409	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Memantine—Alzheimer's disease	0.000557	0.00405	CcSEcCtD
Crizotinib—Hypokalaemia—Rivastigmine—Alzheimer's disease	0.000551	0.004	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Memantine—Alzheimer's disease	0.000545	0.00396	CcSEcCtD
Crizotinib—Muscular weakness—Memantine—Alzheimer's disease	0.000545	0.00396	CcSEcCtD
Crizotinib—Arrhythmia—Galantamine—Alzheimer's disease	0.000543	0.00395	CcSEcCtD
Crizotinib—Muscular weakness—Rivastigmine—Alzheimer's disease	0.000534	0.00388	CcSEcCtD
Crizotinib—Weight decreased—Donepezil—Alzheimer's disease	0.000533	0.00387	CcSEcCtD
Crizotinib—Malnutrition—Galantamine—Alzheimer's disease	0.000529	0.00385	CcSEcCtD
Crizotinib—Pneumonia—Donepezil—Alzheimer's disease	0.000528	0.00384	CcSEcCtD
Crizotinib—Infestation NOS—Donepezil—Alzheimer's disease	0.000525	0.00381	CcSEcCtD
Crizotinib—Infestation—Donepezil—Alzheimer's disease	0.000525	0.00381	CcSEcCtD
Crizotinib—Dysgeusia—Galantamine—Alzheimer's disease	0.000518	0.00377	CcSEcCtD
Crizotinib—Neutropenia—Memantine—Alzheimer's disease	0.0005	0.00363	CcSEcCtD
Crizotinib—Vision blurred—Galantamine—Alzheimer's disease	0.000499	0.00362	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Memantine—Alzheimer's disease	0.000497	0.00361	CcSEcCtD
Crizotinib—Anaemia—Galantamine—Alzheimer's disease	0.000489	0.00355	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Rivastigmine—Alzheimer's disease	0.000486	0.00353	CcSEcCtD
Crizotinib—Weight decreased—Memantine—Alzheimer's disease	0.000484	0.00351	CcSEcCtD
Crizotinib—Bradycardia—Donepezil—Alzheimer's disease	0.00048	0.00349	CcSEcCtD
Crizotinib—Pneumonia—Memantine—Alzheimer's disease	0.000479	0.00348	CcSEcCtD
Crizotinib—Infestation NOS—Memantine—Alzheimer's disease	0.000477	0.00346	CcSEcCtD
Crizotinib—Infestation—Memantine—Alzheimer's disease	0.000477	0.00346	CcSEcCtD
Crizotinib—Syncope—Galantamine—Alzheimer's disease	0.000475	0.00345	CcSEcCtD
Crizotinib—Weight decreased—Rivastigmine—Alzheimer's disease	0.000473	0.00344	CcSEcCtD
Crizotinib—Pneumonia—Rivastigmine—Alzheimer's disease	0.000469	0.00341	CcSEcCtD
Crizotinib—Hypoaesthesia—Donepezil—Alzheimer's disease	0.000469	0.00341	CcSEcCtD
Crizotinib—Neuropathy peripheral—Memantine—Alzheimer's disease	0.000467	0.00339	CcSEcCtD
Crizotinib—Infestation—Rivastigmine—Alzheimer's disease	0.000466	0.00339	CcSEcCtD
Crizotinib—Infestation NOS—Rivastigmine—Alzheimer's disease	0.000466	0.00339	CcSEcCtD
Crizotinib—Urinary tract disorder—Donepezil—Alzheimer's disease	0.000465	0.00338	CcSEcCtD
Crizotinib—Loss of consciousness—Galantamine—Alzheimer's disease	0.000465	0.00338	CcSEcCtD
Crizotinib—Oedema peripheral—Donepezil—Alzheimer's disease	0.000464	0.00337	CcSEcCtD
Crizotinib—Urethral disorder—Donepezil—Alzheimer's disease	0.000462	0.00336	CcSEcCtD
Crizotinib—Neuropathy peripheral—Rivastigmine—Alzheimer's disease	0.000457	0.00332	CcSEcCtD
Crizotinib—Visual impairment—Donepezil—Alzheimer's disease	0.000454	0.0033	CcSEcCtD
Crizotinib—Hepatobiliary disease—Memantine—Alzheimer's disease	0.000451	0.00328	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Galantamine—Alzheimer's disease	0.000447	0.00325	CcSEcCtD
Crizotinib—Hepatobiliary disease—Rivastigmine—Alzheimer's disease	0.000441	0.0032	CcSEcCtD
Crizotinib—Bradycardia—Memantine—Alzheimer's disease	0.000436	0.00316	CcSEcCtD
Crizotinib—Bradycardia—Rivastigmine—Alzheimer's disease	0.000426	0.0031	CcSEcCtD
Crizotinib—Hypoaesthesia—Memantine—Alzheimer's disease	0.000426	0.00309	CcSEcCtD
Crizotinib—Shock—Galantamine—Alzheimer's disease	0.000425	0.00309	CcSEcCtD
Crizotinib—Nervous system disorder—Galantamine—Alzheimer's disease	0.000424	0.00308	CcSEcCtD
Crizotinib—Urinary tract disorder—Memantine—Alzheimer's disease	0.000422	0.00307	CcSEcCtD
Crizotinib—Oedema peripheral—Memantine—Alzheimer's disease	0.000421	0.00306	CcSEcCtD
Crizotinib—Arrhythmia—Donepezil—Alzheimer's disease	0.000421	0.00306	CcSEcCtD
Crizotinib—Skin disorder—Galantamine—Alzheimer's disease	0.00042	0.00305	CcSEcCtD
Crizotinib—Urethral disorder—Memantine—Alzheimer's disease	0.000419	0.00305	CcSEcCtD
Crizotinib—MET—nervous system—Alzheimer's disease	0.000418	0.00354	CbGeAlD
Crizotinib—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.000416	0.00303	CcSEcCtD
Crizotinib—EPHA8—cerebellum—Alzheimer's disease	0.000416	0.00352	CbGeAlD
Crizotinib—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000413	0.003	CcSEcCtD
Crizotinib—TBK1—telencephalon—Alzheimer's disease	0.000413	0.00349	CbGeAlD
Crizotinib—PTK2—telencephalon—Alzheimer's disease	0.000413	0.00349	CbGeAlD
Crizotinib—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.000412	0.003	CcSEcCtD
Crizotinib—Visual impairment—Memantine—Alzheimer's disease	0.000412	0.003	CcSEcCtD
Crizotinib—Urethral disorder—Rivastigmine—Alzheimer's disease	0.00041	0.00298	CcSEcCtD
Crizotinib—Malnutrition—Donepezil—Alzheimer's disease	0.00041	0.00298	CcSEcCtD
Crizotinib—TYK2—telencephalon—Alzheimer's disease	0.00041	0.00347	CbGeAlD
Crizotinib—JAK2—forebrain—Alzheimer's disease	0.000406	0.00343	CbGeAlD
Crizotinib—IRAK1—telencephalon—Alzheimer's disease	0.000405	0.00343	CbGeAlD
Crizotinib—CDK7—nervous system—Alzheimer's disease	0.000404	0.00342	CbGeAlD
Crizotinib—Visual impairment—Rivastigmine—Alzheimer's disease	0.000403	0.00293	CcSEcCtD
Crizotinib—MET—central nervous system—Alzheimer's disease	0.000402	0.0034	CbGeAlD
Crizotinib—Dysgeusia—Donepezil—Alzheimer's disease	0.000402	0.00292	CcSEcCtD
Crizotinib—Eye disorder—Memantine—Alzheimer's disease	0.0004	0.00291	CcSEcCtD
Crizotinib—RPS6KB1—telencephalon—Alzheimer's disease	0.000397	0.00336	CbGeAlD
Crizotinib—Cardiac disorder—Memantine—Alzheimer's disease	0.000397	0.00289	CcSEcCtD
Crizotinib—MET—cerebellum—Alzheimer's disease	0.000393	0.00333	CbGeAlD
Crizotinib—AXL—telencephalon—Alzheimer's disease	0.000393	0.00333	CbGeAlD
Crizotinib—SRC—embryo—Alzheimer's disease	0.000393	0.00332	CbGeAlD
Crizotinib—Eye disorder—Rivastigmine—Alzheimer's disease	0.000391	0.00284	CcSEcCtD
Crizotinib—MAP4K5—forebrain—Alzheimer's disease	0.000391	0.00331	CbGeAlD
Crizotinib—CDK7—central nervous system—Alzheimer's disease	0.000389	0.00329	CbGeAlD
Crizotinib—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000388	0.00282	CcSEcCtD
Crizotinib—Paraesthesia—Galantamine—Alzheimer's disease	0.000388	0.00282	CcSEcCtD
Crizotinib—Vision blurred—Donepezil—Alzheimer's disease	0.000387	0.00281	CcSEcCtD
Crizotinib—ACVR1B—nervous system—Alzheimer's disease	0.000386	0.00327	CbGeAlD
Crizotinib—EPHA3—nervous system—Alzheimer's disease	0.000386	0.00327	CbGeAlD
Crizotinib—Mediastinal disorder—Memantine—Alzheimer's disease	0.000386	0.0028	CcSEcCtD
Crizotinib—PRKD1—brain—Alzheimer's disease	0.000384	0.00325	CbGeAlD
Crizotinib—Arrhythmia—Memantine—Alzheimer's disease	0.000382	0.00278	CcSEcCtD
Crizotinib—CDK7—cerebellum—Alzheimer's disease	0.00038	0.00322	CbGeAlD
Crizotinib—Dyspepsia—Galantamine—Alzheimer's disease	0.00038	0.00276	CcSEcCtD
Crizotinib—Anaemia—Donepezil—Alzheimer's disease	0.000379	0.00275	CcSEcCtD
Crizotinib—SIK2—brain—Alzheimer's disease	0.000379	0.00321	CbGeAlD
Crizotinib—LIMK1—brain—Alzheimer's disease	0.000379	0.00321	CbGeAlD
Crizotinib—SLK—telencephalon—Alzheimer's disease	0.000378	0.0032	CbGeAlD
Crizotinib—TAOK2—cerebellum—Alzheimer's disease	0.000377	0.00319	CbGeAlD
Crizotinib—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000377	0.00274	CcSEcCtD
Crizotinib—EPHB4—telencephalon—Alzheimer's disease	0.000376	0.00318	CbGeAlD
Crizotinib—Decreased appetite—Galantamine—Alzheimer's disease	0.000375	0.00273	CcSEcCtD
Crizotinib—Arrhythmia—Rivastigmine—Alzheimer's disease	0.000374	0.00272	CcSEcCtD
Crizotinib—EPHB6—forebrain—Alzheimer's disease	0.000374	0.00316	CbGeAlD
Crizotinib—JAK2—telencephalon—Alzheimer's disease	0.000373	0.00316	CbGeAlD
Crizotinib—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000373	0.00271	CcSEcCtD
Crizotinib—Malnutrition—Memantine—Alzheimer's disease	0.000372	0.00271	CcSEcCtD
Crizotinib—Fatigue—Galantamine—Alzheimer's disease	0.000372	0.00271	CcSEcCtD
Crizotinib—ACVR1B—central nervous system—Alzheimer's disease	0.000372	0.00315	CbGeAlD
Crizotinib—EPHA3—central nervous system—Alzheimer's disease	0.000372	0.00315	CbGeAlD
Crizotinib—Constipation—Galantamine—Alzheimer's disease	0.000369	0.00268	CcSEcCtD
Crizotinib—PRKD3—brain—Alzheimer's disease	0.000369	0.00313	CbGeAlD
Crizotinib—EPHA6—nervous system—Alzheimer's disease	0.000368	0.00312	CbGeAlD
Crizotinib—JAK3—nervous system—Alzheimer's disease	0.000368	0.00312	CbGeAlD
Crizotinib—Syncope—Donepezil—Alzheimer's disease	0.000368	0.00267	CcSEcCtD
Crizotinib—DCLK1—nervous system—Alzheimer's disease	0.000366	0.0031	CbGeAlD
Crizotinib—Dysgeusia—Memantine—Alzheimer's disease	0.000365	0.00265	CcSEcCtD
Crizotinib—Malnutrition—Rivastigmine—Alzheimer's disease	0.000364	0.00265	CcSEcCtD
Crizotinib—ACVR1B—cerebellum—Alzheimer's disease	0.000363	0.00308	CbGeAlD
Crizotinib—STK4—nervous system—Alzheimer's disease	0.000362	0.00306	CbGeAlD
Crizotinib—Loss of consciousness—Donepezil—Alzheimer's disease	0.00036	0.00262	CcSEcCtD
Crizotinib—DSTYK—brain—Alzheimer's disease	0.00036	0.00305	CbGeAlD
Crizotinib—MAP4K5—telencephalon—Alzheimer's disease	0.00036	0.00304	CbGeAlD
Crizotinib—TEK—telencephalon—Alzheimer's disease	0.00036	0.00304	CbGeAlD
Crizotinib—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000357	0.00259	CcSEcCtD
Crizotinib—TAOK3—forebrain—Alzheimer's disease	0.000357	0.00302	CbGeAlD
Crizotinib—EPHA6—central nervous system—Alzheimer's disease	0.000355	0.003	CbGeAlD
Crizotinib—JAK3—central nervous system—Alzheimer's disease	0.000355	0.003	CbGeAlD
Crizotinib—CSF1R—embryo—Alzheimer's disease	0.000353	0.00298	CbGeAlD
Crizotinib—DCLK1—central nervous system—Alzheimer's disease	0.000352	0.00298	CbGeAlD
Crizotinib—LTK—brain—Alzheimer's disease	0.000352	0.00298	CbGeAlD
Crizotinib—CASK—brain—Alzheimer's disease	0.000352	0.00298	CbGeAlD
Crizotinib—Vision blurred—Memantine—Alzheimer's disease	0.000351	0.00255	CcSEcCtD
Crizotinib—STK4—central nervous system—Alzheimer's disease	0.000348	0.00295	CbGeAlD
Crizotinib—SRC—forebrain—Alzheimer's disease	0.000347	0.00294	CbGeAlD
Crizotinib—JAK3—cerebellum—Alzheimer's disease	0.000347	0.00293	CbGeAlD
Crizotinib—DCLK1—cerebellum—Alzheimer's disease	0.000345	0.00292	CbGeAlD
Crizotinib—Anaemia—Memantine—Alzheimer's disease	0.000344	0.0025	CcSEcCtD
Crizotinib—EPHB6—telencephalon—Alzheimer's disease	0.000344	0.00291	CbGeAlD
Crizotinib—Vision blurred—Rivastigmine—Alzheimer's disease	0.000343	0.0025	CcSEcCtD
Crizotinib—FER—nervous system—Alzheimer's disease	0.000342	0.00289	CbGeAlD
Crizotinib—ALK—nervous system—Alzheimer's disease	0.000342	0.00289	CbGeAlD
Crizotinib—EPHA5—nervous system—Alzheimer's disease	0.000342	0.00289	CbGeAlD
Crizotinib—TYRO3—nervous system—Alzheimer's disease	0.000342	0.00289	CbGeAlD
Crizotinib—Body temperature increased—Galantamine—Alzheimer's disease	0.000341	0.00248	CcSEcCtD
Crizotinib—MAPK7—brain—Alzheimer's disease	0.000341	0.00289	CbGeAlD
Crizotinib—STK4—cerebellum—Alzheimer's disease	0.00034	0.00288	CbGeAlD
Crizotinib—LYN—nervous system—Alzheimer's disease	0.00034	0.00288	CbGeAlD
Crizotinib—EPHA8—brain—Alzheimer's disease	0.000338	0.00286	CbGeAlD
Crizotinib—FES—brain—Alzheimer's disease	0.000338	0.00286	CbGeAlD
Crizotinib—Anaemia—Rivastigmine—Alzheimer's disease	0.000337	0.00245	CcSEcCtD
Crizotinib—MAP3K19—nervous system—Alzheimer's disease	0.000335	0.00283	CbGeAlD
Crizotinib—BMPR1B—nervous system—Alzheimer's disease	0.000335	0.00283	CbGeAlD
Crizotinib—Oedema—Donepezil—Alzheimer's disease	0.000335	0.00243	CcSEcCtD
Crizotinib—Syncope—Memantine—Alzheimer's disease	0.000334	0.00243	CcSEcCtD
Crizotinib—Leukopenia—Memantine—Alzheimer's disease	0.000333	0.00242	CcSEcCtD
Crizotinib—Infection—Donepezil—Alzheimer's disease	0.000333	0.00242	CcSEcCtD
Crizotinib—YES1—telencephalon—Alzheimer's disease	0.000332	0.00281	CbGeAlD
Crizotinib—Shock—Donepezil—Alzheimer's disease	0.000329	0.00239	CcSEcCtD
Crizotinib—ALK—central nervous system—Alzheimer's disease	0.000329	0.00279	CbGeAlD
Crizotinib—TYRO3—central nervous system—Alzheimer's disease	0.000329	0.00279	CbGeAlD
Crizotinib—FER—central nervous system—Alzheimer's disease	0.000329	0.00279	CbGeAlD
Crizotinib—EPHA5—central nervous system—Alzheimer's disease	0.000329	0.00279	CbGeAlD
Crizotinib—IGF1R—nervous system—Alzheimer's disease	0.000328	0.00278	CbGeAlD
Crizotinib—TNK2—nervous system—Alzheimer's disease	0.000328	0.00278	CbGeAlD
Crizotinib—Nervous system disorder—Donepezil—Alzheimer's disease	0.000328	0.00239	CcSEcCtD
Crizotinib—TAOK3—telencephalon—Alzheimer's disease	0.000328	0.00277	CbGeAlD
Crizotinib—LYN—central nervous system—Alzheimer's disease	0.000327	0.00277	CbGeAlD
Crizotinib—Loss of consciousness—Memantine—Alzheimer's disease	0.000327	0.00238	CcSEcCtD
Crizotinib—Syncope—Rivastigmine—Alzheimer's disease	0.000327	0.00237	CcSEcCtD
Crizotinib—BMPR1B—central nervous system—Alzheimer's disease	0.000322	0.00273	CbGeAlD
Crizotinib—MAP3K19—central nervous system—Alzheimer's disease	0.000322	0.00273	CbGeAlD
Crizotinib—FER—cerebellum—Alzheimer's disease	0.000322	0.00272	CbGeAlD
Crizotinib—TYRO3—cerebellum—Alzheimer's disease	0.000322	0.00272	CbGeAlD
Crizotinib—EPHA5—cerebellum—Alzheimer's disease	0.000322	0.00272	CbGeAlD
Crizotinib—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.00032	0.00233	CcSEcCtD
Crizotinib—SRC—telencephalon—Alzheimer's disease	0.000319	0.0027	CbGeAlD
Crizotinib—TIE1—nervous system—Alzheimer's disease	0.000319	0.0027	CbGeAlD
Crizotinib—MET—brain—Alzheimer's disease	0.000319	0.0027	CbGeAlD
Crizotinib—TNK1—cerebellum—Alzheimer's disease	0.000318	0.00269	CbGeAlD
Crizotinib—TNK2—central nervous system—Alzheimer's disease	0.000316	0.00268	CbGeAlD
Crizotinib—IGF1R—central nervous system—Alzheimer's disease	0.000316	0.00268	CbGeAlD
Crizotinib—BMPR1B—cerebellum—Alzheimer's disease	0.000315	0.00267	CbGeAlD
Crizotinib—CSF1R—forebrain—Alzheimer's disease	0.000312	0.00264	CbGeAlD
Crizotinib—AURKA—nervous system—Alzheimer's disease	0.000311	0.00263	CbGeAlD
Crizotinib—Asthenia—Galantamine—Alzheimer's disease	0.00031	0.00225	CcSEcCtD
Crizotinib—TNK2—cerebellum—Alzheimer's disease	0.000309	0.00262	CbGeAlD
Crizotinib—IGF1R—cerebellum—Alzheimer's disease	0.000309	0.00262	CbGeAlD
Crizotinib—CDK7—brain—Alzheimer's disease	0.000309	0.00261	CbGeAlD
Crizotinib—TESK1—nervous system—Alzheimer's disease	0.000309	0.00261	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000308	0.00224	CcSEcCtD
Crizotinib—TIE1—central nervous system—Alzheimer's disease	0.000308	0.0026	CbGeAlD
Crizotinib—TAOK2—brain—Alzheimer's disease	0.000306	0.00259	CbGeAlD
Crizotinib—MAP4K2—cerebellum—Alzheimer's disease	0.000305	0.00258	CbGeAlD
Crizotinib—Oedema—Memantine—Alzheimer's disease	0.000304	0.00221	CcSEcCtD
Crizotinib—Infection—Memantine—Alzheimer's disease	0.000302	0.00219	CcSEcCtD
Crizotinib—STK3—cerebellum—Alzheimer's disease	0.000301	0.00254	CbGeAlD
Crizotinib—TIE1—cerebellum—Alzheimer's disease	0.000301	0.00254	CbGeAlD
Crizotinib—Paraesthesia—Donepezil—Alzheimer's disease	0.000301	0.00218	CcSEcCtD
Crizotinib—MERTK—nervous system—Alzheimer's disease	0.0003	0.00254	CbGeAlD
Crizotinib—AURKA—central nervous system—Alzheimer's disease	0.0003	0.00254	CbGeAlD
Crizotinib—Shock—Memantine—Alzheimer's disease	0.000299	0.00217	CcSEcCtD
Crizotinib—Dyspnoea—Donepezil—Alzheimer's disease	0.000298	0.00217	CcSEcCtD
Crizotinib—Nervous system disorder—Memantine—Alzheimer's disease	0.000298	0.00217	CcSEcCtD
Crizotinib—Oedema—Rivastigmine—Alzheimer's disease	0.000297	0.00216	CcSEcCtD
Crizotinib—TESK1—central nervous system—Alzheimer's disease	0.000297	0.00252	CbGeAlD
Crizotinib—Diarrhoea—Galantamine—Alzheimer's disease	0.000296	0.00215	CcSEcCtD
Crizotinib—Infection—Rivastigmine—Alzheimer's disease	0.000295	0.00215	CcSEcCtD
Crizotinib—Skin disorder—Memantine—Alzheimer's disease	0.000295	0.00215	CcSEcCtD
Crizotinib—EPHA3—brain—Alzheimer's disease	0.000295	0.0025	CbGeAlD
Crizotinib—ACVR1B—brain—Alzheimer's disease	0.000295	0.0025	CbGeAlD
Crizotinib—Dyspepsia—Donepezil—Alzheimer's disease	0.000295	0.00214	CcSEcCtD
Crizotinib—LIMK2—nervous system—Alzheimer's disease	0.000294	0.00249	CbGeAlD
Crizotinib—Shock—Rivastigmine—Alzheimer's disease	0.000293	0.00213	CcSEcCtD
Crizotinib—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.000292	0.00212	CcSEcCtD
Crizotinib—Decreased appetite—Donepezil—Alzheimer's disease	0.000291	0.00211	CcSEcCtD
Crizotinib—MAP3K12—nervous system—Alzheimer's disease	0.000291	0.00246	CbGeAlD
Crizotinib—ACVR1—nervous system—Alzheimer's disease	0.000291	0.00246	CbGeAlD
Crizotinib—TESK1—cerebellum—Alzheimer's disease	0.000291	0.00246	CbGeAlD
Crizotinib—MERTK—central nervous system—Alzheimer's disease	0.000289	0.00245	CbGeAlD
Crizotinib—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000289	0.0021	CcSEcCtD
Crizotinib—Skin disorder—Rivastigmine—Alzheimer's disease	0.000289	0.0021	CcSEcCtD
Crizotinib—Fatigue—Donepezil—Alzheimer's disease	0.000289	0.0021	CcSEcCtD
Crizotinib—CSF1R—telencephalon—Alzheimer's disease	0.000287	0.00243	CbGeAlD
Crizotinib—Constipation—Donepezil—Alzheimer's disease	0.000286	0.00208	CcSEcCtD
Crizotinib—Dizziness—Galantamine—Alzheimer's disease	0.000286	0.00208	CcSEcCtD
Crizotinib—STK35—nervous system—Alzheimer's disease	0.000285	0.00241	CbGeAlD
Crizotinib—LIMK2—central nervous system—Alzheimer's disease	0.000283	0.00239	CbGeAlD
Crizotinib—MERTK—cerebellum—Alzheimer's disease	0.000283	0.00239	CbGeAlD
Crizotinib—EPHA6—brain—Alzheimer's disease	0.000282	0.00238	CbGeAlD
Crizotinib—JAK3—brain—Alzheimer's disease	0.000282	0.00238	CbGeAlD
Crizotinib—DCLK1—brain—Alzheimer's disease	0.00028	0.00237	CbGeAlD
Crizotinib—MAP3K12—central nervous system—Alzheimer's disease	0.00028	0.00237	CbGeAlD
Crizotinib—ACVR1—central nervous system—Alzheimer's disease	0.00028	0.00237	CbGeAlD
Crizotinib—ABL1—embryo—Alzheimer's disease	0.000279	0.00236	CbGeAlD
Crizotinib—PLK4—brain—Alzheimer's disease	0.000278	0.00235	CbGeAlD
Crizotinib—STK4—brain—Alzheimer's disease	0.000276	0.00234	CbGeAlD
Crizotinib—LIMK2—cerebellum—Alzheimer's disease	0.000276	0.00234	CbGeAlD
Crizotinib—NUAK2—cerebellum—Alzheimer's disease	0.000275	0.00233	CbGeAlD
Crizotinib—Vomiting—Galantamine—Alzheimer's disease	0.000275	0.002	CcSEcCtD
Crizotinib—STK35—central nervous system—Alzheimer's disease	0.000274	0.00232	CbGeAlD
Crizotinib—BMP2K—nervous system—Alzheimer's disease	0.000274	0.00232	CbGeAlD
Crizotinib—MAP3K12—cerebellum—Alzheimer's disease	0.000273	0.00231	CbGeAlD
Crizotinib—ACVR1—cerebellum—Alzheimer's disease	0.000273	0.00231	CbGeAlD
Crizotinib—FLT3—cerebellum—Alzheimer's disease	0.000273	0.00231	CbGeAlD
Crizotinib—Paraesthesia—Memantine—Alzheimer's disease	0.000273	0.00198	CcSEcCtD
Crizotinib—Rash—Galantamine—Alzheimer's disease	0.000272	0.00198	CcSEcCtD
Crizotinib—Dermatitis—Galantamine—Alzheimer's disease	0.000272	0.00198	CcSEcCtD
Crizotinib—Dyspnoea—Memantine—Alzheimer's disease	0.000271	0.00197	CcSEcCtD
Crizotinib—STK35—cerebellum—Alzheimer's disease	0.000268	0.00227	CbGeAlD
Crizotinib—Dyspepsia—Memantine—Alzheimer's disease	0.000268	0.00194	CcSEcCtD
Crizotinib—Paraesthesia—Rivastigmine—Alzheimer's disease	0.000267	0.00194	CcSEcCtD
Crizotinib—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000265	0.00193	CcSEcCtD
Crizotinib—PTK2B—nervous system—Alzheimer's disease	0.000265	0.00224	CbGeAlD
Crizotinib—Body temperature increased—Donepezil—Alzheimer's disease	0.000265	0.00192	CcSEcCtD
Crizotinib—Decreased appetite—Memantine—Alzheimer's disease	0.000264	0.00192	CcSEcCtD
Crizotinib—BMP2K—central nervous system—Alzheimer's disease	0.000264	0.00223	CbGeAlD
Crizotinib—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000262	0.00191	CcSEcCtD
Crizotinib—Fatigue—Memantine—Alzheimer's disease	0.000262	0.0019	CcSEcCtD
Crizotinib—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000262	0.0019	CcSEcCtD
Crizotinib—EPHA5—brain—Alzheimer's disease	0.000261	0.00221	CbGeAlD
Crizotinib—TYRO3—brain—Alzheimer's disease	0.000261	0.00221	CbGeAlD
Crizotinib—ALK—brain—Alzheimer's disease	0.000261	0.00221	CbGeAlD
Crizotinib—FER—brain—Alzheimer's disease	0.000261	0.00221	CbGeAlD
Crizotinib—ABL2—cerebellum—Alzheimer's disease	0.000261	0.00221	CbGeAlD
Crizotinib—Constipation—Memantine—Alzheimer's disease	0.00026	0.00189	CcSEcCtD
Crizotinib—LYN—brain—Alzheimer's disease	0.00026	0.0022	CbGeAlD
Crizotinib—TNK1—brain—Alzheimer's disease	0.000259	0.00219	CbGeAlD
Crizotinib—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000258	0.00188	CcSEcCtD
Crizotinib—BMP2K—cerebellum—Alzheimer's disease	0.000258	0.00218	CbGeAlD
Crizotinib—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000257	0.00187	CcSEcCtD
Crizotinib—Nausea—Galantamine—Alzheimer's disease	0.000257	0.00186	CcSEcCtD
Crizotinib—Fatigue—Rivastigmine—Alzheimer's disease	0.000256	0.00186	CcSEcCtD
Crizotinib—MAP4K1—brain—Alzheimer's disease	0.000256	0.00217	CbGeAlD
Crizotinib—MAP3K19—brain—Alzheimer's disease	0.000256	0.00217	CbGeAlD
Crizotinib—BMPR1B—brain—Alzheimer's disease	0.000256	0.00217	CbGeAlD
Crizotinib—PTK2B—central nervous system—Alzheimer's disease	0.000255	0.00216	CbGeAlD
Crizotinib—Constipation—Rivastigmine—Alzheimer's disease	0.000254	0.00185	CcSEcCtD
Crizotinib—EPHA4—nervous system—Alzheimer's disease	0.000254	0.00215	CbGeAlD
Crizotinib—IGF1R—brain—Alzheimer's disease	0.000251	0.00212	CbGeAlD
Crizotinib—TNK2—brain—Alzheimer's disease	0.000251	0.00212	CbGeAlD
Crizotinib—PTK2B—cerebellum—Alzheimer's disease	0.000249	0.00211	CbGeAlD
Crizotinib—MAP3K2—nervous system—Alzheimer's disease	0.000249	0.00211	CbGeAlD
Crizotinib—MAP4K2—brain—Alzheimer's disease	0.000248	0.00209	CbGeAlD
Crizotinib—RIPK2—cerebellum—Alzheimer's disease	0.000247	0.00209	CbGeAlD
Crizotinib—EPHA4—central nervous system—Alzheimer's disease	0.000244	0.00207	CbGeAlD
Crizotinib—TIE1—brain—Alzheimer's disease	0.000244	0.00207	CbGeAlD
Crizotinib—STK3—brain—Alzheimer's disease	0.000244	0.00207	CbGeAlD
Crizotinib—TBK1—nervous system—Alzheimer's disease	0.000244	0.00206	CbGeAlD
Crizotinib—PTK2—nervous system—Alzheimer's disease	0.000244	0.00206	CbGeAlD
Crizotinib—TYK2—nervous system—Alzheimer's disease	0.000242	0.00205	CbGeAlD
Crizotinib—Body temperature increased—Memantine—Alzheimer's disease	0.00024	0.00175	CcSEcCtD
Crizotinib—Asthenia—Donepezil—Alzheimer's disease	0.00024	0.00175	CcSEcCtD
Crizotinib—MAP3K2—central nervous system—Alzheimer's disease	0.00024	0.00203	CbGeAlD
Crizotinib—EPHA4—cerebellum—Alzheimer's disease	0.000239	0.00202	CbGeAlD
Crizotinib—AURKA—brain—Alzheimer's disease	0.000238	0.00201	CbGeAlD
Crizotinib—TESK1—brain—Alzheimer's disease	0.000236	0.002	CbGeAlD
Crizotinib—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000235	0.00171	CcSEcCtD
Crizotinib—TBK1—central nervous system—Alzheimer's disease	0.000235	0.00199	CbGeAlD
Crizotinib—PTK2—central nervous system—Alzheimer's disease	0.000235	0.00199	CbGeAlD
Crizotinib—RPS6KB1—nervous system—Alzheimer's disease	0.000234	0.00198	CbGeAlD
Crizotinib—MAP3K2—cerebellum—Alzheimer's disease	0.000234	0.00198	CbGeAlD
Crizotinib—TYK2—central nervous system—Alzheimer's disease	0.000233	0.00197	CbGeAlD
Crizotinib—FGR—nervous system—Alzheimer's disease	0.000233	0.00197	CbGeAlD
Crizotinib—AXL—nervous system—Alzheimer's disease	0.000232	0.00196	CbGeAlD
Crizotinib—MERTK—brain—Alzheimer's disease	0.00023	0.00194	CbGeAlD
Crizotinib—TBK1—cerebellum—Alzheimer's disease	0.000229	0.00194	CbGeAlD
Crizotinib—PTK2—cerebellum—Alzheimer's disease	0.000229	0.00194	CbGeAlD
Crizotinib—Diarrhoea—Donepezil—Alzheimer's disease	0.000229	0.00166	CcSEcCtD
Crizotinib—TYK2—cerebellum—Alzheimer's disease	0.000228	0.00193	CbGeAlD
Crizotinib—ABL1—telencephalon—Alzheimer's disease	0.000227	0.00192	CbGeAlD
Crizotinib—RPS6KB1—central nervous system—Alzheimer's disease	0.000226	0.00191	CbGeAlD
Crizotinib—IRAK1—cerebellum—Alzheimer's disease	0.000225	0.0019	CbGeAlD
Crizotinib—LIMK2—brain—Alzheimer's disease	0.000225	0.0019	CbGeAlD
Crizotinib—FGR—central nervous system—Alzheimer's disease	0.000224	0.0019	CbGeAlD
Crizotinib—NUAK2—brain—Alzheimer's disease	0.000224	0.00189	CbGeAlD
Crizotinib—AXL—central nervous system—Alzheimer's disease	0.000223	0.00189	CbGeAlD
Crizotinib—MAP3K12—brain—Alzheimer's disease	0.000222	0.00188	CbGeAlD
Crizotinib—ACVR1—brain—Alzheimer's disease	0.000222	0.00188	CbGeAlD
Crizotinib—Dizziness—Donepezil—Alzheimer's disease	0.000221	0.00161	CcSEcCtD
Crizotinib—RPS6KB1—cerebellum—Alzheimer's disease	0.000221	0.00187	CbGeAlD
Crizotinib—JAK2—nervous system—Alzheimer's disease	0.00022	0.00186	CbGeAlD
Crizotinib—AXL—cerebellum—Alzheimer's disease	0.000218	0.00185	CbGeAlD
Crizotinib—Asthenia—Memantine—Alzheimer's disease	0.000218	0.00158	CcSEcCtD
Crizotinib—STK35—brain—Alzheimer's disease	0.000218	0.00184	CbGeAlD
Crizotinib—EPHA2—nervous system—Alzheimer's disease	0.000218	0.00184	CbGeAlD
Crizotinib—Asthenia—Rivastigmine—Alzheimer's disease	0.000213	0.00155	CcSEcCtD
Crizotinib—Vomiting—Donepezil—Alzheimer's disease	0.000213	0.00155	CcSEcCtD
Crizotinib—MAP4K5—nervous system—Alzheimer's disease	0.000212	0.0018	CbGeAlD
Crizotinib—TEK—nervous system—Alzheimer's disease	0.000212	0.0018	CbGeAlD
Crizotinib—MAP3K3—nervous system—Alzheimer's disease	0.000212	0.0018	CbGeAlD
Crizotinib—ABL2—brain—Alzheimer's disease	0.000212	0.0018	CbGeAlD
Crizotinib—JAK2—central nervous system—Alzheimer's disease	0.000212	0.00179	CbGeAlD
Crizotinib—Rash—Donepezil—Alzheimer's disease	0.000211	0.00153	CcSEcCtD
Crizotinib—Dermatitis—Donepezil—Alzheimer's disease	0.000211	0.00153	CcSEcCtD
Crizotinib—SLK—cerebellum—Alzheimer's disease	0.00021	0.00178	CbGeAlD
Crizotinib—EPHA2—central nervous system—Alzheimer's disease	0.00021	0.00177	CbGeAlD
Crizotinib—BMP2K—brain—Alzheimer's disease	0.000209	0.00177	CbGeAlD
Crizotinib—EPHB4—cerebellum—Alzheimer's disease	0.000209	0.00177	CbGeAlD
Crizotinib—Diarrhoea—Memantine—Alzheimer's disease	0.000208	0.00151	CcSEcCtD
Crizotinib—JAK2—cerebellum—Alzheimer's disease	0.000207	0.00175	CbGeAlD
Crizotinib—MAP3K3—central nervous system—Alzheimer's disease	0.000204	0.00173	CbGeAlD
Crizotinib—MAP4K5—central nervous system—Alzheimer's disease	0.000204	0.00173	CbGeAlD
Crizotinib—TEK—central nervous system—Alzheimer's disease	0.000204	0.00173	CbGeAlD
Crizotinib—Diarrhoea—Rivastigmine—Alzheimer's disease	0.000203	0.00148	CcSEcCtD
Crizotinib—EPHB6—nervous system—Alzheimer's disease	0.000203	0.00172	CbGeAlD
Crizotinib—PTK2B—brain—Alzheimer's disease	0.000202	0.00171	CbGeAlD
Crizotinib—Dizziness—Memantine—Alzheimer's disease	0.000201	0.00146	CcSEcCtD
Crizotinib—RIPK2—brain—Alzheimer's disease	0.000201	0.0017	CbGeAlD
Crizotinib—MAP4K5—cerebellum—Alzheimer's disease	0.0002	0.00169	CbGeAlD
Crizotinib—MAP3K3—cerebellum—Alzheimer's disease	0.0002	0.00169	CbGeAlD
Crizotinib—TEK—cerebellum—Alzheimer's disease	0.0002	0.00169	CbGeAlD
Crizotinib—Nausea—Donepezil—Alzheimer's disease	0.000199	0.00144	CcSEcCtD
Crizotinib—Dizziness—Rivastigmine—Alzheimer's disease	0.000197	0.00143	CcSEcCtD
Crizotinib—YES1—nervous system—Alzheimer's disease	0.000196	0.00166	CbGeAlD
Crizotinib—EPHB6—central nervous system—Alzheimer's disease	0.000195	0.00165	CbGeAlD
Crizotinib—STK10—nervous system—Alzheimer's disease	0.000194	0.00164	CbGeAlD
Crizotinib—EPHA4—brain—Alzheimer's disease	0.000194	0.00164	CbGeAlD
Crizotinib—TAOK3—nervous system—Alzheimer's disease	0.000194	0.00164	CbGeAlD
Crizotinib—Vomiting—Memantine—Alzheimer's disease	0.000193	0.0014	CcSEcCtD
Crizotinib—Rash—Memantine—Alzheimer's disease	0.000192	0.00139	CcSEcCtD
Crizotinib—Dermatitis—Memantine—Alzheimer's disease	0.000191	0.00139	CcSEcCtD
Crizotinib—EPHB6—cerebellum—Alzheimer's disease	0.000191	0.00162	CbGeAlD
Crizotinib—MAP3K2—brain—Alzheimer's disease	0.00019	0.00161	CbGeAlD
Crizotinib—Vomiting—Rivastigmine—Alzheimer's disease	0.000189	0.00137	CcSEcCtD
Crizotinib—YES1—central nervous system—Alzheimer's disease	0.000189	0.0016	CbGeAlD
Crizotinib—SRC—nervous system—Alzheimer's disease	0.000189	0.0016	CbGeAlD
Crizotinib—Rash—Rivastigmine—Alzheimer's disease	0.000187	0.00136	CcSEcCtD
Crizotinib—Dermatitis—Rivastigmine—Alzheimer's disease	0.000187	0.00136	CcSEcCtD
Crizotinib—STK10—central nervous system—Alzheimer's disease	0.000187	0.00158	CbGeAlD
Crizotinib—TAOK3—central nervous system—Alzheimer's disease	0.000186	0.00158	CbGeAlD
Crizotinib—PTK2—brain—Alzheimer's disease	0.000186	0.00158	CbGeAlD
Crizotinib—TBK1—brain—Alzheimer's disease	0.000186	0.00158	CbGeAlD
Crizotinib—TYK2—brain—Alzheimer's disease	0.000185	0.00157	CbGeAlD
Crizotinib—YES1—cerebellum—Alzheimer's disease	0.000184	0.00156	CbGeAlD
Crizotinib—STK10—cerebellum—Alzheimer's disease	0.000183	0.00155	CbGeAlD
Crizotinib—IRAK1—brain—Alzheimer's disease	0.000183	0.00155	CbGeAlD
Crizotinib—TAOK3—cerebellum—Alzheimer's disease	0.000182	0.00154	CbGeAlD
Crizotinib—SRC—central nervous system—Alzheimer's disease	0.000182	0.00154	CbGeAlD
Crizotinib—Nausea—Memantine—Alzheimer's disease	0.000181	0.00131	CcSEcCtD
Crizotinib—RPS6KB1—brain—Alzheimer's disease	0.000179	0.00152	CbGeAlD
Crizotinib—FGR—brain—Alzheimer's disease	0.000178	0.00151	CbGeAlD
Crizotinib—SRC—cerebellum—Alzheimer's disease	0.000177	0.0015	CbGeAlD
Crizotinib—AXL—brain—Alzheimer's disease	0.000177	0.0015	CbGeAlD
Crizotinib—Nausea—Rivastigmine—Alzheimer's disease	0.000177	0.00128	CcSEcCtD
Crizotinib—SLK—brain—Alzheimer's disease	0.000171	0.00145	CbGeAlD
Crizotinib—EPHB4—brain—Alzheimer's disease	0.00017	0.00144	CbGeAlD
Crizotinib—CSF1R—nervous system—Alzheimer's disease	0.000169	0.00143	CbGeAlD
Crizotinib—JAK2—brain—Alzheimer's disease	0.000168	0.00142	CbGeAlD
Crizotinib—EPHA2—brain—Alzheimer's disease	0.000166	0.00141	CbGeAlD
Crizotinib—CSF1R—central nervous system—Alzheimer's disease	0.000163	0.00138	CbGeAlD
Crizotinib—MAP4K5—brain—Alzheimer's disease	0.000162	0.00137	CbGeAlD
Crizotinib—MAP3K3—brain—Alzheimer's disease	0.000162	0.00137	CbGeAlD
Crizotinib—TEK—brain—Alzheimer's disease	0.000162	0.00137	CbGeAlD
Crizotinib—CSF1R—cerebellum—Alzheimer's disease	0.000159	0.00135	CbGeAlD
Crizotinib—EPHB6—brain—Alzheimer's disease	0.000155	0.00131	CbGeAlD
Crizotinib—YES1—brain—Alzheimer's disease	0.00015	0.00127	CbGeAlD
Crizotinib—STK10—brain—Alzheimer's disease	0.000149	0.00126	CbGeAlD
Crizotinib—TAOK3—brain—Alzheimer's disease	0.000148	0.00125	CbGeAlD
Crizotinib—ABCB1—blood vessel—Alzheimer's disease	0.000145	0.00123	CbGeAlD
Crizotinib—SRC—brain—Alzheimer's disease	0.000144	0.00122	CbGeAlD
Crizotinib—ABL1—nervous system—Alzheimer's disease	0.000134	0.00113	CbGeAlD
Crizotinib—CSF1R—brain—Alzheimer's disease	0.000129	0.0011	CbGeAlD
Crizotinib—ABL1—central nervous system—Alzheimer's disease	0.000129	0.00109	CbGeAlD
Crizotinib—ABL1—cerebellum—Alzheimer's disease	0.000126	0.00107	CbGeAlD
Crizotinib—ABL1—brain—Alzheimer's disease	0.000102	0.000866	CbGeAlD
Crizotinib—ABCB1—embryo—Alzheimer's disease	8.67e-05	0.000734	CbGeAlD
Crizotinib—ABCB1—forebrain—Alzheimer's disease	7.67e-05	0.000649	CbGeAlD
Crizotinib—ABCB1—telencephalon—Alzheimer's disease	7.05e-05	0.000597	CbGeAlD
Crizotinib—CYP3A4—nervous system—Alzheimer's disease	5.88e-05	0.000498	CbGeAlD
Crizotinib—CYP3A4—central nervous system—Alzheimer's disease	5.66e-05	0.000479	CbGeAlD
Crizotinib—ABCB1—nervous system—Alzheimer's disease	4.16e-05	0.000352	CbGeAlD
Crizotinib—ABCB1—central nervous system—Alzheimer's disease	4.01e-05	0.000339	CbGeAlD
Crizotinib—ABCB1—cerebellum—Alzheimer's disease	3.92e-05	0.000331	CbGeAlD
Crizotinib—ABCB1—brain—Alzheimer's disease	3.18e-05	0.000269	CbGeAlD
Crizotinib—LCK—Immune System—BCL2—Alzheimer's disease	1.08e-06	5.21e-06	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—AKT1—Alzheimer's disease	1.07e-06	5.19e-06	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—AKT1—Alzheimer's disease	1.07e-06	5.18e-06	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—AKT1—Alzheimer's disease	1.07e-06	5.16e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—MAPK8—Alzheimer's disease	1.06e-06	5.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1R—Alzheimer's disease	1.06e-06	5.14e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCR5—Alzheimer's disease	1.06e-06	5.13e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP2D6—Alzheimer's disease	1.06e-06	5.13e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MAPK8—Alzheimer's disease	1.06e-06	5.13e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—GSK3B—Alzheimer's disease	1.06e-06	5.11e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ESR1—Alzheimer's disease	1.05e-06	5.09e-06	CbGpPWpGaD
Crizotinib—CDK7—Disease—AKT1—Alzheimer's disease	1.05e-06	5.09e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARGC1A—Alzheimer's disease	1.05e-06	5.08e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CREB1—Alzheimer's disease	1.05e-06	5.07e-06	CbGpPWpGaD
Crizotinib—BLK—Immune System—AKT1—Alzheimer's disease	1.05e-06	5.06e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—HMOX1—Alzheimer's disease	1.04e-06	5.06e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—INS—Alzheimer's disease	1.04e-06	5.04e-06	CbGpPWpGaD
Crizotinib—FGR—Immune System—AKT1—Alzheimer's disease	1.04e-06	5.04e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—F2—Alzheimer's disease	1.04e-06	5.03e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—Alzheimer's disease	1.04e-06	5.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR2A—Alzheimer's disease	1.04e-06	5.02e-06	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—AKT1—Alzheimer's disease	1.03e-06	5e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—Alzheimer's disease	1.03e-06	5e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—Alzheimer's disease	1.03e-06	4.98e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—Alzheimer's disease	1.03e-06	4.97e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—GSK3B—Alzheimer's disease	1.02e-06	4.93e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—LPL—Alzheimer's disease	1.02e-06	4.93e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CASP3—Alzheimer's disease	1.02e-06	4.93e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOTCH1—Alzheimer's disease	1.02e-06	4.92e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CREB1—Alzheimer's disease	1.01e-06	4.89e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—Alzheimer's disease	1.01e-06	4.89e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MEF2C—Alzheimer's disease	1.01e-06	4.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—AKT1—Alzheimer's disease	1.01e-06	4.88e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—Alzheimer's disease	1.01e-06	4.87e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—INS—Alzheimer's disease	1.01e-06	4.87e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—BCHE—Alzheimer's disease	1e-06	4.86e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CASP3—Alzheimer's disease	1e-06	4.86e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MAPK8—Alzheimer's disease	9.96e-07	4.82e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—Alzheimer's disease	9.96e-07	4.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRKCG—Alzheimer's disease	9.91e-07	4.8e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL2—Alzheimer's disease	9.9e-07	4.79e-06	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—AKT1—Alzheimer's disease	9.8e-07	4.74e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF1—Alzheimer's disease	9.73e-07	4.71e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CALM1—Alzheimer's disease	9.68e-07	4.69e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NGF—Alzheimer's disease	9.65e-07	4.67e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—LEP—Alzheimer's disease	9.65e-07	4.67e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APOE—Alzheimer's disease	9.65e-07	4.67e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—Alzheimer's disease	9.59e-07	4.64e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—Alzheimer's disease	9.57e-07	4.63e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CAV1—Alzheimer's disease	9.56e-07	4.63e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—LPL—Alzheimer's disease	9.56e-07	4.63e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—GSK3B—Alzheimer's disease	9.54e-07	4.62e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—Alzheimer's disease	9.53e-07	4.61e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—BCL2—Alzheimer's disease	9.53e-07	4.61e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CASP3—Alzheimer's disease	9.52e-07	4.61e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—Alzheimer's disease	9.51e-07	4.61e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PLCB1—Alzheimer's disease	9.48e-07	4.59e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CREB1—Alzheimer's disease	9.46e-07	4.58e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—Alzheimer's disease	9.44e-07	4.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—INS—Alzheimer's disease	9.41e-07	4.56e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR5—Alzheimer's disease	9.39e-07	4.54e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK8—Alzheimer's disease	9.36e-07	4.53e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—Alzheimer's disease	9.34e-07	4.52e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL2—Alzheimer's disease	9.26e-07	4.48e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CASP3—Alzheimer's disease	9.25e-07	4.48e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—Alzheimer's disease	9.24e-07	4.47e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—Alzheimer's disease	9.24e-07	4.47e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK8—Alzheimer's disease	9.23e-07	4.47e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ESR1—Alzheimer's disease	9.21e-07	4.46e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ABCA1—Alzheimer's disease	9.19e-07	4.45e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR2A—Alzheimer's disease	9.19e-07	4.45e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—Alzheimer's disease	9.19e-07	4.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TPI1—Alzheimer's disease	9.16e-07	4.44e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CHAT—Alzheimer's disease	9.16e-07	4.44e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—Alzheimer's disease	9.14e-07	4.42e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—Alzheimer's disease	9.12e-07	4.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1—Alzheimer's disease	9.1e-07	4.41e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—F2—Alzheimer's disease	9.1e-07	4.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOTCH1—Alzheimer's disease	8.91e-07	4.31e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—Alzheimer's disease	8.85e-07	4.28e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—Alzheimer's disease	8.82e-07	4.27e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—Alzheimer's disease	8.82e-07	4.27e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MAOB—Alzheimer's disease	8.79e-07	4.25e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK8—Alzheimer's disease	8.75e-07	4.24e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK8—Alzheimer's disease	8.72e-07	4.22e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—Alzheimer's disease	8.68e-07	4.2e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—Alzheimer's disease	8.65e-07	4.18e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—Alzheimer's disease	8.64e-07	4.18e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—Alzheimer's disease	8.6e-07	4.16e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CALM1—Alzheimer's disease	8.57e-07	4.15e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—Alzheimer's disease	8.54e-07	4.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—LEP—Alzheimer's disease	8.54e-07	4.13e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOE—Alzheimer's disease	8.54e-07	4.13e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—Alzheimer's disease	8.53e-07	4.13e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—Alzheimer's disease	8.52e-07	4.12e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK8—Alzheimer's disease	8.5e-07	4.11e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—Alzheimer's disease	8.47e-07	4.1e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—Alzheimer's disease	8.47e-07	4.1e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—Alzheimer's disease	8.47e-07	4.1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CAV1—Alzheimer's disease	8.46e-07	4.1e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	8.46e-07	4.09e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—Alzheimer's disease	8.42e-07	4.08e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—Alzheimer's disease	8.41e-07	4.07e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—Alzheimer's disease	8.39e-07	4.06e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—Alzheimer's disease	8.36e-07	4.05e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—GSK3B—Alzheimer's disease	8.36e-07	4.04e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—Alzheimer's disease	8.32e-07	4.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CREB1—Alzheimer's disease	8.29e-07	4.01e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—Alzheimer's disease	8.25e-07	3.99e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—INS—Alzheimer's disease	8.24e-07	3.99e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—Alzheimer's disease	8.2e-07	3.97e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—A2M—Alzheimer's disease	8.17e-07	3.95e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ESR1—Alzheimer's disease	8.16e-07	3.95e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—Alzheimer's disease	8.11e-07	3.93e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—Alzheimer's disease	8.08e-07	3.91e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—F2—Alzheimer's disease	8.06e-07	3.9e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CALM1—Alzheimer's disease	8.04e-07	3.89e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—Alzheimer's disease	8.01e-07	3.88e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—Alzheimer's disease	7.98e-07	3.86e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1—Alzheimer's disease	7.97e-07	3.86e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CAV1—Alzheimer's disease	7.94e-07	3.84e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—Alzheimer's disease	7.93e-07	3.84e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARGC1A—Alzheimer's disease	7.92e-07	3.83e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HMOX1—Alzheimer's disease	7.88e-07	3.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOTCH1—Alzheimer's disease	7.88e-07	3.82e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—Alzheimer's disease	7.88e-07	3.82e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—Alzheimer's disease	7.85e-07	3.8e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—Alzheimer's disease	7.85e-07	3.8e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—Alzheimer's disease	7.82e-07	3.79e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—Alzheimer's disease	7.81e-07	3.78e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—Alzheimer's disease	7.79e-07	3.77e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—Alzheimer's disease	7.75e-07	3.75e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—Alzheimer's disease	7.74e-07	3.75e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK8—Alzheimer's disease	7.72e-07	3.74e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—Alzheimer's disease	7.62e-07	3.69e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—Alzheimer's disease	7.61e-07	3.68e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—Alzheimer's disease	7.51e-07	3.63e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—Alzheimer's disease	7.5e-07	3.63e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—Alzheimer's disease	7.49e-07	3.62e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—Alzheimer's disease	7.42e-07	3.59e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GSK3B—Alzheimer's disease	7.4e-07	3.58e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CREB1—Alzheimer's disease	7.34e-07	3.55e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INS—Alzheimer's disease	7.3e-07	3.53e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—Alzheimer's disease	7.23e-07	3.5e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—LPL—Alzheimer's disease	7.21e-07	3.49e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—Alzheimer's disease	7.2e-07	3.49e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—Alzheimer's disease	7.18e-07	3.48e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—Alzheimer's disease	7.18e-07	3.48e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—Alzheimer's disease	7.15e-07	3.46e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ACHE—Alzheimer's disease	7.11e-07	3.44e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—Alzheimer's disease	7.07e-07	3.42e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—Alzheimer's disease	7.06e-07	3.42e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—Alzheimer's disease	7.03e-07	3.4e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	7.02e-07	3.4e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—Alzheimer's disease	7.01e-07	3.39e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—Alzheimer's disease	6.98e-07	3.38e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—Alzheimer's disease	6.97e-07	3.37e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—Alzheimer's disease	6.96e-07	3.37e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—Alzheimer's disease	6.92e-07	3.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK8—Alzheimer's disease	6.88e-07	3.33e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—INS—Alzheimer's disease	6.84e-07	3.31e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—Alzheimer's disease	6.83e-07	3.3e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—Alzheimer's disease	6.8e-07	3.29e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—Alzheimer's disease	6.77e-07	3.27e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	6.66e-07	3.22e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO1—Alzheimer's disease	6.66e-07	3.22e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—Alzheimer's disease	6.63e-07	3.21e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	6.53e-07	3.16e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—Alzheimer's disease	6.53e-07	3.16e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—Alzheimer's disease	6.49e-07	3.14e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK8—Alzheimer's disease	6.44e-07	3.12e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—Alzheimer's disease	6.44e-07	3.12e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—Alzheimer's disease	6.43e-07	3.11e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—Alzheimer's disease	6.42e-07	3.11e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—Alzheimer's disease	6.4e-07	3.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—Alzheimer's disease	6.36e-07	3.08e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—Alzheimer's disease	6.35e-07	3.08e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—Alzheimer's disease	6.27e-07	3.04e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—Alzheimer's disease	6.24e-07	3.02e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BCHE—Alzheimer's disease	6.19e-07	3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—Alzheimer's disease	6.14e-07	2.97e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—Alzheimer's disease	6.11e-07	2.96e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CALM1—Alzheimer's disease	6.07e-07	2.94e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—Alzheimer's disease	6.04e-07	2.93e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—Alzheimer's disease	6.04e-07	2.92e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—Alzheimer's disease	6e-07	2.9e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAV1—Alzheimer's disease	5.99e-07	2.9e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—Alzheimer's disease	5.98e-07	2.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—Alzheimer's disease	5.95e-07	2.88e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—Alzheimer's disease	5.93e-07	2.87e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—Alzheimer's disease	5.89e-07	2.85e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—Alzheimer's disease	5.87e-07	2.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—Alzheimer's disease	5.87e-07	2.84e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	5.84e-07	2.83e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—Alzheimer's disease	5.83e-07	2.82e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	5.66e-07	2.74e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK8—Alzheimer's disease	5.64e-07	2.73e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—Alzheimer's disease	5.59e-07	2.71e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—Alzheimer's disease	5.57e-07	2.7e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—Alzheimer's disease	5.51e-07	2.67e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—Alzheimer's disease	5.49e-07	2.66e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—Alzheimer's disease	5.46e-07	2.64e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—Alzheimer's disease	5.44e-07	2.63e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—Alzheimer's disease	5.43e-07	2.63e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—Alzheimer's disease	5.43e-07	2.63e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—Alzheimer's disease	5.42e-07	2.62e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—Alzheimer's disease	5.26e-07	2.55e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—Alzheimer's disease	5.21e-07	2.52e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—INS—Alzheimer's disease	5.16e-07	2.5e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—Alzheimer's disease	5.16e-07	2.5e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—Alzheimer's disease	5.14e-07	2.49e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—Alzheimer's disease	5.14e-07	2.49e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—Alzheimer's disease	5.01e-07	2.42e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK8—Alzheimer's disease	4.99e-07	2.42e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—Alzheimer's disease	4.93e-07	2.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	4.88e-07	2.36e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	4.86e-07	2.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—Alzheimer's disease	4.8e-07	2.32e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—Alzheimer's disease	4.78e-07	2.31e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—Alzheimer's disease	4.75e-07	2.3e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—Alzheimer's disease	4.61e-07	2.23e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—Alzheimer's disease	4.55e-07	2.2e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—Alzheimer's disease	4.55e-07	2.2e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—Alzheimer's disease	4.53e-07	2.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—Alzheimer's disease	4.49e-07	2.17e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LPL—Alzheimer's disease	4.44e-07	2.15e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—Alzheimer's disease	4.39e-07	2.13e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—Alzheimer's disease	4.23e-07	2.05e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—Alzheimer's disease	4.2e-07	2.03e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—Alzheimer's disease	4.14e-07	2e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—Alzheimer's disease	4.11e-07	1.99e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—Alzheimer's disease	4.05e-07	1.96e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	4e-07	1.94e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—Alzheimer's disease	3.94e-07	1.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—Alzheimer's disease	3.79e-07	1.84e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CALM1—Alzheimer's disease	3.74e-07	1.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—Alzheimer's disease	3.72e-07	1.8e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAV1—Alzheimer's disease	3.69e-07	1.79e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—Alzheimer's disease	3.6e-07	1.74e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—Alzheimer's disease	3.48e-07	1.69e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—Alzheimer's disease	3.32e-07	1.61e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—Alzheimer's disease	3.24e-07	1.57e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—Alzheimer's disease	3.19e-07	1.54e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—INS—Alzheimer's disease	3.18e-07	1.54e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—Alzheimer's disease	2.94e-07	1.42e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—Alzheimer's disease	2.79e-07	1.35e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—Alzheimer's disease	2.76e-07	1.34e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	2.55e-07	1.24e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—Alzheimer's disease	2.08e-07	1.01e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—Alzheimer's disease	1.28e-07	6.21e-07	CbGpPWpGaD
